
As the Proxy Battle Intensifies, Illumina Implores Shareholders to Reject Carl Icahn’s Board Nominations
In a letter to shareholders on Thursday (March 30, 2023), Illumina warned that Carl Icahn’s three board nominees would “threaten the progress” of the biotech…